Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash from Operations (2019 - 2025)

Pulmonx (LUNG) has disclosed Cash from Operations for 7 consecutive years, with 8170000.0 as the latest value for Q3 2025.

  • Quarterly Cash from Operations fell 13.47% to 8170000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 32000000.0 through Sep 2025, up 3.76% year-over-year, with the annual reading at 31500000.0 for FY2024, 16.25% up from the prior year.
  • Cash from Operations for Q3 2025 was 8170000.0 at Pulmonx, down from 3908000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 3908000.0 in Q2 2025, with the low at 15026000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 9520684.21, with a median of 9564000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations plummeted 65.86% in 2021, then surged 32.62% in 2025.
  • Over 5 years, Cash from Operations stood at 10723000.0 in 2021, then grew by 8.77% to 9783000.0 in 2022, then grew by 13.64% to 8449000.0 in 2023, then increased by 20.7% to 6700000.0 in 2024, then decreased by 21.94% to 8170000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 8170000.0, 3908000.0, and 13222000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.